JP2021514973A5 - - Google Patents

Info

Publication number
JP2021514973A5
JP2021514973A5 JP2020544813A JP2020544813A JP2021514973A5 JP 2021514973 A5 JP2021514973 A5 JP 2021514973A5 JP 2020544813 A JP2020544813 A JP 2020544813A JP 2020544813 A JP2020544813 A JP 2020544813A JP 2021514973 A5 JP2021514973 A5 JP 2021514973A5
Authority
JP
Japan
Prior art keywords
antibody
cdr
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514973A (ja
JP7411559B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/062569 external-priority patent/WO2019104306A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/019566 external-priority patent/WO2019165421A1/en
Publication of JP2021514973A publication Critical patent/JP2021514973A/ja
Publication of JP2021514973A5 publication Critical patent/JP2021514973A5/ja
Priority to JP2023218543A priority Critical patent/JP7705442B2/ja
Application granted granted Critical
Publication of JP7411559B2 publication Critical patent/JP7411559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544813A 2018-02-26 2019-02-26 Anti-muci*抗体を用いた診断法 Active JP7411559B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023218543A JP7705442B2 (ja) 2018-02-26 2023-12-25 Anti-muci*抗体を用いた診断法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862635378P 2018-02-26 2018-02-26
US62/635,378 2018-02-26
US201862640697P 2018-03-09 2018-03-09
US62/640,697 2018-03-09
USPCT/US18/62569 2018-11-27
PCT/US2018/062569 WO2019104306A1 (en) 2017-11-27 2018-11-27 Humanized anti-muc1* antibodies and direct use of cleavage enzyme
US201962791661P 2019-01-11 2019-01-11
US62/791,661 2019-01-11
PCT/US2019/019566 WO2019165421A1 (en) 2018-02-26 2019-02-26 Diagnostic methods using anti-muc1* antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023218543A Division JP7705442B2 (ja) 2018-02-26 2023-12-25 Anti-muci*抗体を用いた診断法

Publications (3)

Publication Number Publication Date
JP2021514973A JP2021514973A (ja) 2021-06-17
JP2021514973A5 true JP2021514973A5 (enExample) 2022-03-07
JP7411559B2 JP7411559B2 (ja) 2024-01-11

Family

ID=67688578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544813A Active JP7411559B2 (ja) 2018-02-26 2019-02-26 Anti-muci*抗体を用いた診断法
JP2023218543A Active JP7705442B2 (ja) 2018-02-26 2023-12-25 Anti-muci*抗体を用いた診断法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023218543A Active JP7705442B2 (ja) 2018-02-26 2023-12-25 Anti-muci*抗体を用いた診断法

Country Status (8)

Country Link
US (3) US11976132B2 (enExample)
EP (1) EP3759145A4 (enExample)
JP (2) JP7411559B2 (enExample)
CN (1) CN112272677B (enExample)
AU (2) AU2019225237B2 (enExample)
CA (1) CA3092247A1 (enExample)
IL (1) IL276925A (enExample)
WO (1) WO2019165421A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変muc1*抗体およびその使用
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
IL294486A (en) * 2020-01-13 2022-09-01 Truebinding Inc Antibodies against gal3 and methods of use
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
JP2023530997A (ja) * 2020-06-19 2023-07-20 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Bst2ロングアイソフォームを標的化する抗bst2抗体
AU2021297535A1 (en) 2020-06-26 2023-02-16 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
GR20200100703A (el) * 2020-11-26 2022-06-08 Icarus Antibodies Ι.Κ.Ε, Μονοκλωνικα αντισωματα εναντι του κορωνοϊου sars-cov-2 και χρησεις αυτων
CN116554317B (zh) * 2022-01-29 2025-02-28 浙江纳米抗体技术中心有限公司 Muc1结合分子及其应用
TW202346330A (zh) 2022-03-18 2023-12-01 美商長典生物晶片股份有限公司 抗豬繁殖與呼吸道綜合症病毒的抗體及其用途
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof
CN117820483B (zh) * 2024-03-01 2024-05-28 北京纳百生物科技有限公司 一种猫n-端脑利钠肽前体蛋白单克隆抗体、检测试纸条及应用
WO2025255276A1 (en) * 2024-06-04 2025-12-11 Fred Hutchinson Cancer Center Anti-whitlow linker binding domains and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9263101A (en) * 2000-09-11 2002-03-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US20100150914A1 (en) 2006-11-09 2010-06-17 Irm Llc Agonist trkb antibodies and uses thereof
JP2015502975A (ja) * 2011-12-22 2015-01-29 ライナット ニューロサイエンス コーポレイション ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
RU2016144178A (ru) * 2014-04-28 2018-05-10 Медисинал Кемистри Фармасьютикалс, Ко., Лтд. Антитело против muc1 или его антигенсвязывающий фрагмент и его применение
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変muc1*抗体およびその使用

Similar Documents

Publication Publication Date Title
JP7254699B2 (ja) 抗bcma重鎖のみ抗体
RU2008149918A (ru) Антитела к nkg2a и их применения
JP7257971B6 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
NZ585559A (en) Humanized antibodies against tl1a
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
JP2018183173A5 (enExample)
JP2014511179A5 (enExample)
JP2018510636A5 (enExample)
JP2021501162A5 (enExample)
JP2017052784A5 (enExample)
JP2017535257A5 (enExample)
JP2017534577A5 (enExample)
RU2012119788A (ru) Связывающие il-1 белки
JP2016512551A5 (enExample)
JP2020513791A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2016510002A5 (enExample)
RU2017126476A (ru) Новые модуляторы и способы их применения
JP2011506483A5 (enExample)
US20110117079A1 (en) Therapeutic dll4 binding proteins
JP2016527225A5 (enExample)
JP2016538318A5 (enExample)
JP2016505546A5 (enExample)
JP2022533538A5 (enExample)
JP2022514734A5 (enExample)